REUTERS - AstraZeneca Pharma India Ltd , a unit of British drugmaker AstraZeneca Plc , said on Friday the floor price for its delisting from the Indian stock exchanges had been set at 854.1 rupees a share.
AstraZeneca said the delisting of the Indian unit and an increase in its ownership would provide it with "greater operational flexibility" to support the company's business in the local market.
AstraZeneca Pharma India's stock has risen nearly 50 percent from the year's low on January 30 to touch 1,092.35 rupees on Friday on delisting expectations, while the Mumbai market rose roughly 12 percent in that period.
The Indian unit's board approved the delisting proposal on March 18.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Sumeet Chatterjee)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app